Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Inflammatory markers may explain COVID-19, diabetes dynamic

Key clinical point: Patients with COVID-19 and diabetes are susceptible to an inflammatory storm.

Major finding: COVID-19 patients with diabetes had higher levels of interleukin-6 (13.7 vs. 4.1 pg/mL, respectively; P < .01), C-reactive protein (76.4 vs. 7.43 mg/L; P < .01), and serum ferritin (764.8 vs. 128.9 ng/mL; P < .01), compared with those without diabetes.

Study details: A retrospective study of 174 patients with COVID-19 (24 with diabetes, 26 without any comorbidities).

Disclosures: The study was funded by the China National Natural Science Foundation. The authors reported no conflicts of interest. Dr. Rettinger has no relevant financial disclosures. Dr. Mirmira is on scientific advisory boards for Veralox Therapeutics, Sigilon Therapeutics, the Indiana Biosciences Research Institute, and the Juvenile Diabetes Research Foundation.


Guo W et al. Diabetes Metab Res Rev. 2020 Mar 31. doi: 10.1002/dmrr.3319.